Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 610 across all filing types
Latest filing 2023-05-12 Capital/Financing Update
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Alligators offentliggör tilläggsprospekt
Capital/Financing Update Classification · 1% confidence The document is a press release from Alligator Bioscience announcing the publication and registration of a 'supplementary prospectus' (tilläggsprospekt) related to a previously announced rights issue. It explicitly states that it is not a prospectus itself, but rather an announcement regarding the availability of the document. Following the 'Menu vs Meal' rule, since this is a short announcement (press release) about the publication of a report/document, it is classified as a Report Publication Announcement.
2023-05-12 Swedish
Alligator publishes supplementary prospectus
Report Publication Announcement Classification · 1% confidence The document is a press release announcing the publication of a 'supplementary prospectus' related to a rights issue. It explicitly states that the prospectus is available on the company's website and provides instructions for investors. Following the 'Menu vs Meal' rule, this document is an announcement of a report (the prospectus) rather than the report itself, making it a Report Publication Announcement (RPA).
2023-05-12 English
Alligator Bioscience and Orion Corporation announce exercise of development option under their 2021 Immuno-oncology Research Collaboration and License Agreement
Regulatory Filings Classification · 1% confidence The document is a press release announcing a specific corporate event: Orion Corporation exercising a development option under a research collaboration agreement with Alligator Bioscience, which triggers a milestone payment. It contains quotes from management, details about the collaboration, and concludes with a statement that the information is 'obliged to make public pursuant to the EU Market Abuse Regulation' and includes links to an attachment (a PDF). This structure—a brief announcement of a material event with regulatory context and an attached document—is characteristic of a general regulatory filing or announcement that doesn't fit the specific financial report categories (like 10-K, IR, ER). Since it is a formal announcement of a material event required for public disclosure, and it doesn't fit the more specific categories like Director's Dealing (DIRS), Capital Change (CAP), or Dividend (DIV), the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements.
2023-05-11 English
Alligator Bioscience och Orion Corporation meddelar att utvecklingsmöjlighet nyttjats inom bolagens immunonkologiska forskningssamarbete och licensavtal från 2021
Regulatory Filings Classification · 1% confidence The document is a press release from Alligator Bioscience announcing that Orion Corporation has exercised an option to advance drug candidates developed under their research collaboration and license agreement. It details a milestone payment and the continuation of development. The text concludes with a statement indicating it is information that Alligator Bioscience is required to disclose under the EU Market Abuse Regulation, and it provides links to the full document (PDF). Since this is an announcement about a corporate event/development (exercise of option/milestone payment) and not the full financial report (10-K, IR) or a standard earnings release (ER), it fits best as a general regulatory announcement or a specific corporate action announcement. Given the context of corporate updates that are mandatory disclosures, and the presence of links to the full filing, it aligns closely with a Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) due to the milestone payment, but RNS is the broader, safer category for mandatory, non-standard financial disclosures. However, looking closely at the definitions, this is a specific corporate development announcement regarding a licensing agreement milestone, which is a form of material non-public information disclosure. It is not a standard earnings release, proxy, or annual report. It is a specific update on a partnership/licensing deal. Since there isn't a specific 'Partnership Update' code, and it's a mandatory disclosure, RNS (Regulatory Filings - general regulatory announcements and fallback) is appropriate. If we consider the nature of the announcement (a milestone payment triggering development continuation), it is a significant corporate event disclosure, which often falls under RNS in many databases when a more specific code isn't available. It is definitely not RPA because the document *is* the announcement, not just an announcement *of* an attached report (though a PDF link is present, the core content is the news itself). I will classify it as RNS as the most appropriate general regulatory disclosure category.
2023-05-11 Swedish
Alligator publishes supplementary prospectus
Report Publication Announcement Classification · 1% confidence The document is titled "ALLIGATOR PUBLISHES SUPPLEMENTARY PROSPECTUS" and explicitly states that it is a press release announcing the publication of a supplementary prospectus related to a Rights Issue. It mentions the approval by the Swedish Financial Supervisory Authority and provides links to the full prospectuses. Crucially, the document itself states: "In accordance with article 2 k of the Prospectus Regulation this press release constitutes an advertisement." This indicates the document is an announcement about the availability of the formal offering documents (Prospectuses), rather than the Prospectus itself or a standard financial report (like 10-K or IR). Since it is an announcement regarding the publication of a formal document, it fits best under Report Publication Announcement (RPA), as it announces the release of the Prospectus supplement. It is not a general regulatory filing (RNS) because it is specific to a report publication.
2023-05-09 English
Alligators offentliggör tilläggsprospekt
Capital/Financing Update Classification · 1% confidence The document is a press release titled "ALLIGATORS OFFENTLIGGÖR TILLÄGGSPROSPEKT" (Alligator Announces Supplementary Prospectus). It explicitly states that a supplementary prospectus has been prepared for a rights issue and that this prospectus was approved by the Swedish Financial Supervisory Authority (Finansinspektionen) on May 9, 2023. The document itself is an announcement about the publication of this prospectus and related rights for investors to withdraw previous applications. Crucially, the final section includes an attachment link titled "Alligators offentliggör tilläggsprospekt" and the text states, "Detta pressmeddelande är inte ett prospekt... Inbjudan till berörda personer att teckna units i Alligator har endast skett genom Prospekten... Detta pressmeddelande utgör marknadsföring i enlighet med artikel 2 k i Prospektförordningen." This structure—a short announcement directing readers to the official document (the Prospectus) and explicitly stating the announcement itself is marketing material—fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since the core action is announcing the publication of a key offering document (the Prospectus/Tilläggsprospekt), RPA is the most specific fit, as it announces the release of a report/offering document, rather than being the report itself (which would likely be classified under CAP if it were the financing document, but this is the announcement of the document). Given the context of announcing the availability of a prospectus, RPA is appropriate, though RNS is a close fallback.
2023-05-09 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.